Investments

Co-Investment
Held / Exited
  • Recipharm logo
    Co-Investment

    Recipharm

    Sweden

    Healthcare & life science
    Healthcare & life science

    Founded in 1995 and headquartered in Stockholm, Recipharm is the #2 largest European Contract Development & Manufacturing Organization and #5 globally. It serves 400 customers from 35 facilities in 10 countries, primarily Europe. As of 2020, Recipharm employed 7,900 people. Recipharm mainly focuses on products, which are in commercial phase, small molecules and finished drug products or advanced delivery systems.

The Ardian team brought a deep sector knowledge, which I think allowed them not only to do a terrific job in that due diligence period, but also meant they could work very efficiently within our deal time frame.

Doug Brody KKR Capital Market

Ardian and Arsenal both want our investments to benefit society and by working together in this case we’ve reduced the time it takes to set up a clinical trial by many months, which means new drugs come to market as quickly and safely as possible.

Steve McLean Partner of Arsenal Capital

During the due diligence phase, we identified Ardian as a future shareholder capable of making a significant contribution to Emera's development. As soon as the transaction closed, we were able to define and launch value-creating initiatives with Naxicap and Ardian, particularly in terms of group structuring, external growth, digital transformation and real estate strategy, in France but also in Spain and other European countries.

Eric Baugas CEO of EMERA